Celltrion/Pfizer's Biosimilar Launch: Three Possible Dates For Inflectra
This article was originally published in PharmAsia News
Executive Summary
Pfizer and Celltrion still face patent questions – and a pesky launch notification issue – after the ground-breaking US approval of their biosimilar version of Janssen's Remicade.